Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MGTX vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGTX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

MGTX Overall Winner 6-Pillar Tally: MGTX 5 – 1 CAPR Matrix Metrics: MGTX 10 – 0 CAPR

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MGTX carries a Unified Composite Score of 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MGTX vs CAPR
MGTX NASDAQ Head-to-Head Winner
MeiraGTx Holdings plc Ordinary Shares
Biological Products, (No Disgnostic Substances)
$8.85
-3.59% 1D
Market Cap $844.2M
TTM Revenue $398M
Forward P/E 64.1x
Beta / 30D Vol 1.65β · 68% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 48.0 Fund 57.0 Flow 70.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.7%), weak momentum, RSI 41
RSI-14: 41.5 · SMA20: $9.39 · SMA50: $10.61
CAPR NASDAQ
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (MGTX 5 – 1 CAPR)

Columns: Metric · MGTX · CAPR
1. Valuation Multiples MGTX
Forward P/E 64.1x 78.7x
Trailing P/E 10.1x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 2.0x 57.8x
2. Growth & Scale MGTX
Revenue Growth (YoY) +8608.6% -7.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $398M $11M
Market Cap $844.2M $595.4M
3. Profitability & Quality MGTX
Gross Margin 97.9% N/A
Operating Margin 46.3% 0.0%
Net Profit Margin 19.9% 0.0%
Return on Equity (ROE) 72.2% -100.5%
4. Balance Sheet & Cash Flow MGTX
Cash Generation (TTM) -$28M -$146M
Cash Flow Margin -7.0% N/A
Net Cash / Leverage $51M Net Cash $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 52.9% (3rd %ile) 637.1% (89th %ile)
Put/Call OI Skew N/A 1.57x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat MGTX
OpEx & R&D Intensity 51.6% of Rev ($205M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MGTX (10) vs CAPR (0)
Institutional Metric MGTX CAPR Criterion Row Edge
Market Capitalization
Scale
$844.2M $595.4M Larger Scale MGTX
Trailing P/E Ratio
Valuation
10.1x 78.7x Lower Multiple MGTX
Forward P/E Ratio
Valuation
64.1x 78.7x Lower Multiple MGTX
Revenue Growth (YoY)
Growth
+8608.6% -7.9% Higher Growth MGTX
Operating Margin (TTM)
Profitability
46.3% 0.0% Higher Margin MGTX
Net Profit Margin
Profitability
19.9% 0.0% Higher Margin MGTX
Return on Equity (ROE)
Capital Efficiency
72.2% -100.5% Higher ROE MGTX
52-Week Range Position
Momentum
26% ($7–$15) 15% ($3–$40) Stronger Trend MGTX
Beta / 30D Volatility
Risk Regime
1.65β · 68% Vol 1.52β · 152% Vol Lower Realized Risk MGTX
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite MGTX
Trailing 12M Revenue (USD)
Operating Scale
$398M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
97.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.0x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($51M Net Cash) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +30.86 pp
MGTX: -4.63% · CAPR: +26.23%
3M Horizon CAPR +55.92 pp
MGTX: -36.29% · CAPR: +19.63%
6M Horizon MGTX +64.73 pp
MGTX: -5.85% · CAPR: -70.58%
1Y Horizon CAPR +39.65 pp
MGTX: +7.14% · CAPR: +46.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MGTX Revenue CAPR Revenue MGTX Op. Margin CAPR Op. Margin Margin Leader
FY2018 N/A $0M N/A -917.0% CAPR
FY2019 $10M $0M -438.4% -769.5% MGTX
FY2020 $20M $0M -401.9% -4412.6% MGTX
FY2021 $40M $0M -193.0% -8549.9% MGTX
FY2022 $20M $0M -730.9% -1163.9% MGTX
FY2023 $10M $30M -977.8% -95.6% CAPR
FY2024 $30M $20M -493.4% -191.1% CAPR
FY2025 $80M N/A -130.2% N/A MGTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MGTX BREAKDOWN
62d in phase · OBV ACCUMULATION
Current IV 52.9%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MGTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MGTX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $844.2M market capitalization and 46.3% operating margin.
OpEx & R&D Reinvestment 51.6% of Rev ($205M)
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MGTX vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, MeiraGTx Holdings plc (MGTX) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MGTX carries a Unified Composite Score of 48.0/100 (HOLD) at $8.85 (64.1x Forward P/E, 46.3% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: MGTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.5); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MGTX leads the Growth & Scale pillar: MGTX posts +8608.6% YoY revenue growth and +0.0% YoY earnings growth on $398M TTM revenue (97.9% gross margin, 46.3% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MGTX cumulative revenue shifted +700.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, MGTX deploys 51.6% of Rev ($205M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

MGTX screens cheaper on headline valuation multiples. MGTX trades at 64.1x Forward P/E, 10.1x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (-7.0% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MGTX (72.2% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MGTX carries 52.9% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.65β · 68% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.